Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion. The drugmaker ...

Eli Lilly's Q4 revenue rose 45% YoY to $13.53B, driven by Mounjaro and Zepbound. Adjusted EPS hit $5.32, beating the $4.94 consensus. 2025 guidance projects $58B-$61B in sales, with a 32% growth ...

Eli Lilly (NYSE:LLY) reported strong Q4 2024 results on Thursday, surpassing Wall Street estimates, driven by a more than twofold increase in sales of its weight loss and diabetes drugs Mounjaro ...

We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters. How we use your information depends on the product and service ...

We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters. How we use your information depends on the product and service ...

With social media's history of hyped-up health trends, does a 'Mounjaro drink' drink deliver results - or is it just another internet myth? From 'sleepy girl cocktails' to 'oatzempic' drinks there ...

Australia 10 Year Government Bond 0.116 4.398% ...

New rules mean people seeking weight loss jabs will need to verify their body mass index by video consultation, in person, or through their GP or medical records, after eating disorder sufferers ...

On Today with Claire Byrne, Maura Fay reports on the rollout of Mounjaro in Ireland and speaks to medical experts about issues surrounding access to this medication. Listen back above. The most ...

US President Donald Trump has suspended tariffs on small packages from China, after his sudden order ending duty-free treatment for shipments worth less than $800 (£645) left the US postal ...

The US Food and Drug Administration (FDA) has declared an end to the shortage of tirzepatide, the active ingredient in Eli Lilly’s popular weight loss medication Zepbound and diabetes drug Mounjaro.